特发性隐匿精子症男性中存在两个隐藏临床亚组的识别
该研究回顾性纳入132例隐匿精子症患者和160例梗阻性无精子症且精子发生完整的对照,采用主成分分析与层次聚类,发现隐匿精子症可分为两个亚组,其睾丸组织组成、睾丸体积和FSH水平不同,但两组间医学辅助生殖结局相当。
要点
- 基于睾丸组织组成、睾丸体积和FSH水平,隐匿精子症患者可分为两个不同亚组。
- 两个隐匿精子症亚组均显示MAGEA4+和Adark精原细胞减少、PIWIL4+精原细胞比例升高。
- 两个隐匿精子症亚组与对照的医学辅助生殖结局相当。
核心结论
- 隐匿精子症患者存在两个基于睾丸组织组成、睾丸体积和FSH水平区分的不同亚组。
研究设计与样本
- 回顾性从临床数据库选取132例在大学医院接受睾丸活检的隐匿精子症患者,并选取160例梗阻性无精子症且精子发生完整的对照,共292例。
- 对全部292例进行内分泌、精液和 histological 参数评估,并对隐匿精子症(n=73)和对照(n=87)评估医学辅助生殖结局。
- 基于聚类分析结果和组织学参数选取39例(对照12例、隐匿精子症27例)进行免疫组化和组织形态计量分析。
主要发现
- 主成分分析和层次聚类揭示三个聚类,其中聚类1包含全部对照和2例隐匿精子症患者,聚类2为隐匿精子症患者,聚类3为隐匿精子症患者。
- 聚类3较聚类2的FSH水平更高(P < 0.001)、睾丸体积更小(P < 0.001)。
- 两个隐匿精子症聚类中MAGEA4+和Adark精原细胞数量更低、PIWIL4+精原细胞比例更高,且与含伸长型精子细胞的曲细精管百分比更低显著相关。
- 对照与两个隐匿精子症聚类的医学辅助生殖结局相当。
关键数值与推荐
- 聚类1由含伸长型精子细胞的曲细精管百分比驱动,包含全部对照患者和2例隐匿精子症患者。
- 聚类2由含精母细胞的曲细精管百分比驱动,均为隐匿精子症患者。
- 聚类3由仅支持细胞表型的曲细精管驱动,均为隐匿精子症患者。
- 聚类2和聚类3中含伸长型精子细胞的曲细精管百分比相当。
临床怎么用
- 作者认为,隐匿精子症患者可分为两个亚组的新见解将有助于战略性地寻找潜在遗传病因。
- 作者认为,两个隐匿精子症亚组共享的精原干细胞 compartment 改变可能代表对精子输出减少的一般反应机制,可能与进展性表型相关。
局限性
- 虽然发现了隐匿精子症患者队列中存在亚组,但仍需进行全面的遗传学分析以揭示可能的不同病因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Are there subgroups among patients with cryptozoospermia pointing to distinct etiologies? SUMMARY ANSWER: We reveal two distinct subgroups of cryptozoospermic (Crypto) patients based on testicular tissue composition, testicular volume, and FSH levels. WHAT IS KNOWN ALREADY: Cryptozoospermic patients present with a sperm concentration below 0.1 million/ml. While the etiology of the severely impaired spermatogenesis remains largely unknown, alterations of the spermatogonial compartment have been reported including a reduction of the reserve stem cells in these patients. STUDY DESIGN, SIZE, DURATION: To assess whether there are distinct subgroups among cryptozoospermic patients, we applied the statistical method of cluster analysis. For this, we retrospectively selected 132 cryptozoospermic patients from a clinical database who underwent a testicular biopsy in the frame of fertility treatment at a university hospital. As controls (Control), we selected 160 patients with obstructive azoospermia and full spermatogenesis. All 292 patients underwent routine evaluation for endocrine, semen, and histological parameters (i.e. the percentage of tubules with elongated spermatids). Moreover, outcome of medically assisted reproduction (MAR) was assessed for cryptozoospermic (n = 73) and Control patients (n = 87), respectively. For in-depth immunohistochemical and histomorphometrical analyses, representative tissue samples from cryptozoospermic (n = 27) and Control patients (n = 12) were selected based on cluster analysis results and histological parameters. PARTICIPANTS/MATERIALS, SETTING, METHODS: This study included two parts: firstly using clinical parameters of the entire cohort of 292 patients, we performed principal component analysis (PCA) followed by hierarchical clustering on principal components (i.e. considering hormonal values, ejaculate parameters, and histological information). Secondly, for histological analyses seminiferous tubules were categorized according to the most advanced germ cell type present in sections stained with Periodic acid Schif. On the selected cohort of 39 patients (12 Control, 27 cryptozoospermic), we performed immunohistochemistry for spermatogonial markers melanoma-associated antigen 4 (MAGEA4) and piwi like RNA-mediated gene silencing 4 (PIWIL4) followed by quantitative analyses. Moreover, the morphologically defined Adark spermatogonia, which are considered to be the reserve stem cells, were quantified. MAIN RESULTS AND THE ROLE OF CHANCE: The PCA and hierarchical clustering revealed three different clusters, one of them containing all Control samples. The main factors driving the sorting of patients to the clusters were the percentage of tubules with elongated spermatids (Cluster 1, all Control patients and two cryptozoospermic patients), the percentage of tubules with spermatocytes (Cluster 2, cryptozoospermic patients), and tubules showing a Sertoli cells only phenotype (Cluster 3, cryptozoospermic patients). Importantly, the percentage of tubules containing elongated spermatids was comparable between Clusters 2 and 3. Additional differences were higher FSH levels (P < 0.001) and lower testicular volumes (P < 0.001) in Cluster 3 compared to Cluster 2. In the spermatogonial compartment of both cryptozoospermic Clusters, we found lower numbers of MAGEA4+ and Adark spermatogonia but higher proportions of PIWIL4+ spermatogonia, which were significantly correlated with a lower percentage of tubules containing elongated spermatids. In line with this common alteration, the outcome of MAR was comparable between Controls as well as both cryptozoospermic Clusters. LIMITATIONS, REASONS FOR CAUTION: While we have uncovered the existence of subgroups within the cohort of cryptozoospermic patients, comprehensive genetic analyses remain to be performed to unravel potentially distinct etiologies. WIDER IMPLICATIONS OF THE FINDINGS: The novel insight that cryptozoospermic patients can be divided into two subgroups will facilitate the strategic search for underlying genetic etiologies. Moreover, the shared alterations of the spermatogonial stem cell compartment between the two cryptozoospermic subgroups could represent a general response mechanism to the reduced output of sperm, which may be associated with a progressive phenotype. This study therefore offers novel approaches towards the understanding of the etiology underlying the reduced sperm formation in cryptozoospermic patients. STUDY FUNDING/COMPETING INTEREST(S): German research foundation CRU 326 (grants to: SDP, NN). Moreover, we thank the Faculty of Medicine of the University of Münster for the financial support of Lena Charlotte Schülke through the MedK-program. We acknowledge support from the Open Access Publication Fund of the University of Münster. The authors have no potential conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Schülke LC, Wistuba J, Nordhoff V, et al. Identification of two hidden clinical subgroups among men with idiopathic cryptozoospermia. Hum Reprod. 2024. PMID: 38365879. doi:10.1093/humrep/deae013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。